Precept Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

Precept Management’s Portfolio SBBP Stock Details SBBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-345,000	Closed	-$2.07M	–	94
2018 Q2	$2.07M	Sell	345,000 -125,000	-27%	-$915K	0.62%	44
2018 Q1	$4.16M	Buy	+470,000	New	+$3.52M	1.73%	19

Other funds holding SBBP

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Lyon Street Capital Sausalito, California $67M AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Harvest Capital Strategies San Francisco, California $73.7M AUM 7.47% 1-Year Est. Return

Precept Management's SBBP Position: Q3 2018 in Review

Precept Management sold out of Strongbridge Biopharma plc. (SBBP) in Q3 2018, closing a stake of 345,000 shares — an estimated $2.07M sold.

Precept Management first reported a position in SBBP in Q1 2018 and held it in 2 quarters. The position peaked at $4.16M in Q1 2018. 49 funds tracked by Wall St. Rank hold SBBP as of Q3 2018.

Precept Management reported no remaining Strongbridge Biopharma plc. position as of Q3 2018 after selling out during the quarter.
Precept Management sold 345,000 Strongbridge Biopharma plc. shares in Q3 2018, an estimated $2.07M.
Precept Management first reported a position in Strongbridge Biopharma plc. in Q1 2018 and held it in 2 quarters.
Precept Management's Strongbridge Biopharma plc. position peaked at $4.16M in Q1 2018.
49 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q3 2018.

Based on Precept Management's 13F filing for Q3 2018, filed 14 Nov 2018.